Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021;11(1):3-8.
doi: 10.3233/JPD-212573.

COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel?

Bastiaan R Bloem  1 , Claudia Trenkwalder  2 , Alvaro Sanchez-Ferro  3 , Lorraine V Kalia  4 , Roy Alcalay  5 , Han-Lin Chiang  6 , Un Jung Kang  7 , Christopher Goetz  8 , Patrik Brundin  9 , Stella M Papa  10
Affiliations
Review

COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel?

Bastiaan R Bloem et al. J Parkinsons Dis. 2021.

Abstract

Several COVID-19 vaccines have recently been approved for emergency use according to governmental immunization programs. The arrival of these vaccines has created hope for people with Parkinson's disease (PD), as this can help to mitigate their risk of becoming infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which can lead to serious, life-threatening disease, at least among those with more advanced PD. However, both persons with PD and physicians looking after these individuals have expressed concerns about the vaccine's efficacy and safety in the specific context of PD and its symptomatic treatment. Here, we discuss our perspective on these concerns, based on our interpretation of the literature plus the unfolding experience with widespread vaccination in the population at large. Because the benefits and risks of COVID-19 vaccines do not appear to be different than in the general population, we recommend COVID-19 vaccination with approved vaccines to persons with PD, unless there is a specific contraindication. Some caution seems warranted in very frail and terminally ill elderly persons with PD living in long-term care facilities.

Keywords: COVID-19; Parkinson’s disease; SARS-CoV-2; adverse effects; efficacy; movement disorders; pandemic; safety; vaccination; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to report.

References

    1. Antonini A, Leta V, Teo J, Chaudhuri KR (2020) Outcome of Parkinson’s disease patients affected by COVID-19. Mov Disord 35, 905–908. - PMC - PubMed
    1. Cilia R, Bonvegna S, Straccia G, Andreasi NG, Elia AE, Romito LM, Devigili G, Cereda E, Eleopra R (2020) Effects of COVID-19 on Parkinson’s disease clinical features: A community-based case-control study. Mov Disord 35, 1287–1292. - PMC - PubMed
    1. Zhang Q, Schultz JL, Aldridge GM, Simmering JE, Narayanan NS (2020) Coronavirus disease 2019 case fatality and Parkinson’s disease. Mov Disord 35, 1914–1915. - PMC - PubMed
    1. Fasano A, Elia AE, Dallocchio C, Canesi M, Alimonti D, Sorbera C, Alonso-Canovas A, Pezzoli G (2020) Predictors of COVID-19 outcome in Parkinson’s disease. Parkinsonism Relat Disord 78, 134–137. - PMC - PubMed
    1. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ (2020) Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: A systematic review and meta-analysis. Lancet 395, 1973–1987. - PMC - PubMed

Substances